{"id":"W3011470625","doi":"10.1016/j.eururo.2019.09.035","title":"EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Cilag; Sanofi Pasteur; Pharmacyclics; Chugai Pharmaceutical; Genentech; European Association of Urology; European Society for Medical Oncology; Astellas Pharma; Eisai; Bayer; Universitat Autònoma de Barcelona; Cancer Research UK; GlaxoSmithKline; UroGen Pharma; MSD Australia; EMD Serono; Radboud Universitair Medisch Centrum; Pfizer; Incyte; Medac; Ipsen; Clovis Oncology; Alere; Bayer HealthCare; Sanofi; Amgen; Radboud Universiteit; Novartis; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Consensus conference; Bladder cancer; MEDLINE; Family medicine; Urology; General surgery; Oncology; Cancer; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2446872,0.001954154,0.001802299,0.009086622,0.00337886,0.005305027,0.004069732,0.0060297,0.01178898],"category_scores_gemma":[0.1573336,0.001128292,0.002375809,0.005611199,0.002093226,0.004933894,0.01711731,0.005976845,0.004897633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005624777,"about_ca_system_score_gemma":0.05915152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002954364,"about_ca_topic_score_gemma":0.0033726,"domain_scores_codex":[0.8641453,0.09237023,0.01285885,0.003357609,0.02171773,0.005550195],"domain_scores_gemma":[0.8291933,0.03273979,0.01078709,0.00909249,0.09729432,0.02089286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008754118,0.00107279,0.008968442,0.006785545,0.000334564,0.001444873,0.02023409,0.002388649,0.007167227,0.01381221,0.3439667,0.5929495],"study_design_scores_gemma":[0.0003397666,0.0008597763,0.01866894,0.02251815,0.0002397589,0.002332143,0.02203966,0.005790739,0.005076053,0.01826332,0.9035701,0.0003015521],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"other","genre_scores_codex":[0.09328298,0.05306208,0.3772798,0.2505182,0.03908914,0.06083529,0.005982236,0.002365489,0.1175848],"genre_scores_gemma":[0.2383756,0.02463529,0.6326603,0.02048538,0.003329692,0.0315342,0.009830775,0.001171045,0.03797768],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.2446872,"threshold_uncertainty_score":0.9314351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02578443331298604,"score_gpt":0.3183087991993905,"score_spread":0.2925243658864045,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}